Danish biotech business Genmab
* Claims reveals European regulatory submission for
ofatumumab in blend along with fludarabine then cyclophosphamide
with regard to relapsed CLL
* Claims CLL is the the majority of normal type of leukemia in the
Western world, accounting with regard to 30 percent of adult leukemias
* Claims application was sent by Novartis under
ofatumumab collaboration in between Novartis then Genmab
* Claims application is based about outcomes from a set III
study
* Claims top-line outcomes from this test were showed in
April
2015
Resource text message with regard to Eikon:
More business coverage:
(Mentioning by Copenhagen Newsroom)
